rs2288904 — SLC44A2 R154Q

SLC44A2 R154Q — The Variant That Silences Neutrophil Traps

Venous thromboembolism — comprising deep vein thrombosis (DVT) and pulmonary embolism (PE) — affects roughly 1–2 per 1,000 people per year and is the third leading cause of cardiovascular death globally. Most genetic risk factors operate through classical coagulation pathways: clotting factors, fibrinolysis, anticoagulant proteins. The SLC44A2 R154Q variant is different. It works through an entirely unexpected route — controlling whether blood flow can trigger neutrophils to spin out their own DNA as a clot-promoting scaffold.

The SLC44A2 gene¹¹ SLC44A2 gene
Solute Carrier Family 44 Member 2, a choline transporter expressed on neutrophils and platelets encodes a transmembrane protein whose primary function in the innate immune context is to serve as a docking point for activated platelets. Its discovery as a VTE locus surprised the field because it sits entirely outside the classical hemostasis pathway.

The Mechanism

When blood slows or pools in a vein — during prolonged immobility, post-surgery, or following endothelial injury — von Willebrand factor becomes activated and primes nearby platelets to expose their integrin αIIbβ3²² αIIbβ3
glycoprotein IIb/IIIa, the primary fibrinogen receptor on activated platelets. Activated αIIbβ3 then binds to SLC44A2 expressed on the surface of circulating neutrophils. This platelet-neutrophil handshake, driven by blood shear forces, triggers the neutrophil to expel its own nuclear DNA decorated with antimicrobial proteins — forming neutrophil extracellular traps³³ neutrophil extracellular traps
NETs: web-like chromatin structures that can trap pathogens but also act as highly prothrombotic scaffolds that capture platelets and activate the coagulation cascade. These NETs accelerate clot formation in a flow-dependent manner.

The R154Q variant introduces a glutamine at position 154, which sits in an extracellular loop of SLC44A2 that directly contacts αIIbβ3. The substitution severely impairs binding to both activated αIIbβ3 and VWF-primed platelets⁴⁴ severely impairs binding to both activated αIIbβ3 and VWF-primed platelets
Constantinescu-Bercu et al. eLife 2020 directly demonstrated this using neutrophils homozygous for the R154Q polymorphism. Without that binding, the mechanical signal never reaches the neutrophil's nucleus — no NETs form, and the prothrombotic scaffold is never laid down. The protective effect is allele-dose-dependent: AA homozygotes lose the interaction almost completely; AG heterozygotes show intermediate impairment.

The Evidence

The SLC44A2 locus was first identified as a VTE susceptibility locus⁵⁵ first identified as a VTE susceptibility locus
Germain M et al. Meta-analysis of 65,734 individuals. American Journal of Human Genetics 2015 in a two-stage meta-analysis of 7,507 cases and 52,632 controls in discovery, with replication in 3,009 cases and 2,586 controls. The G allele reached genome-wide significance (OR 1.21, P=2.75×10⁻¹⁵) — a strikingly large effect for a common variant in a GWAS. Crucially, the association did not involve classical hemostatic plasma markers (factors V, VIII, VWF, fibrinogen, D-dimer), suggesting a distinct pathway.

The effect was replicated and refined⁶⁶ replicated and refined
Klarin D et al. Nature Genetics 2019 in a dataset of 26,066 VTE cases and 624,053 controls (OR 1.12, P=4×10⁻²⁴). The cross-ancestry investigation⁷⁷ cross-ancestry investigation
Thibord F et al. Circulation 2022 of 81,669 participants confirmed the locus across European, African, and Hispanic populations among 135 identified VTE loci.

The mechanistic dissection⁸⁸ mechanistic dissection
Constantinescu-Bercu A et al. eLife 2020 is particularly important: the R154Q polymorphism is present in approximately 22% of the population (the A allele frequency). Using primary human neutrophils homozygous for R154Q, the eLife study directly demonstrated abrogated platelet binding and abolished flow-dependent NETosis. This study established the causal mechanism rather than just statistical association — a rare achievement for a GWAS-identified variant.

Mouse models corroborate the platelet-neutrophil interaction⁹⁹ corroborate the platelet-neutrophil interaction
Tilburg J et al. Journal of Thrombosis and Haemostasis 2020: SLC44A2-deficient mice produced significantly smaller thrombi in stenosis-induced (flow-restriction) models but not in hypercoagulability models, confirming the mechanism is specifically flow-dependent and distinct from classical coagulation.

The A allele also associates with approximately 10% reduced multiple sclerosis risk¹⁰¹⁰ 10% reduced multiple sclerosis risk
IMSGC, Nature Genetics 2013 (OR ~1.1 for G at MS P=2×10⁻¹¹), suggesting that SLC44A2-mediated neutrophil activation may have broader roles in immune-mediated diseases beyond thrombosis.

Practical Actions

The protective A allele is relatively common (~22% globally, ~34% in East Asians, ~6% in Africans). AA homozygotes have approximately 30% lower VTE risk; AG heterozygotes have an intermediate reduction of roughly 10–15%. For GG carriers who lack the protective allele, awareness of VTE-promoting circumstances and risk factor management becomes more important: prolonged immobility during long flights or hospital stays, oral contraceptives or hormone therapy, surgery, and cancer are the major modifiable and situational risk factors that interact with underlying genetic predisposition.

Because the SLC44A2 mechanism is NETosis-dependent and flow-dependent, interventions that promote venous blood flow (walking, compression stockings during immobilization) are particularly relevant mechanistically for GG carriers — these reduce the stasis conditions that trigger the platelet-SLC44A2 NETosis cascade in the first place.

Interactions

The SLC44A2 R154Q protective signal is mechanistically independent of classical coagulation pathway variants (Factor V Leiden rs6025, Prothrombin G20210A rs1799963, MTHFR C677T rs1801133). Individuals who carry both classical risk variants and the SLC44A2 GG genotype could have additive VTE risk through orthogonal pathways. Conversely, AA homozygotes who also carry Factor V Leiden have partially offset risks, since the NETosis arm is suppressed even if the coagulation cascade is hyperactivated. There are currently no published studies quantifying the combined effect of SLC44A2 R154Q with classical thrombophilia alleles, making this a candidate for compound action modeling.